An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma.

Trial Profile

An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Cephalon; Teva Pharmaceutical Industries
  • Most Recent Events

    • 14 Feb 2012 Actual patient number (40) added as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top